Neurogene Inc.: directors' dealings · United States · SEC (Form 4)

About Neurogene Inc.

Neurogene Inc. (ticker: NGNE) is a U.S.-based biotechnology company listed on the Nasdaq market in the United States. It is focused on developing genetic medicines for rare neurological diseases, with a clinical-stage profile that makes the company highly dependent on trial execution, regulatory milestones and capital-market access. Neurogene was founded in January 2018 and is headquartered in New York, placing it in one of the most important U.S. hubs for biopharma research, financing and talent. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000037/ngne-20260331.htm?utm_source=openai)) The company’s lead asset is NGN-401, a gene therapy being developed for Rett syndrome, a severe neurodevelopmental disorder with limited treatment options. Neurogene has positioned NGN-401 as its primary value driver and has advanced it through clinical development, including a registrational study. The company has also emphasized its in-house manufacturing capabilities and broader development infrastructure, which it believes can support product quality, development timelines and the transition from clinical to commercial operations. Neurogene also references its EXACT platform and a broader pipeline, but the investment thesis is still largely centered on NGN-401. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-recent-achievements-and-anticipated-2026-key?utm_source=openai)) From a competitive standpoint, Neurogene operates in a niche but crowded gene-therapy landscape where differentiation is driven by clinical data, durability, safety, manufacturing reliability and eventual reimbursement potential. Its strategic focus on rare neurological diseases gives it a clear thematic identity, and management has repeatedly framed NGN-401 as potentially best-in-class for Rett syndrome. At the same time, the company remains exposed to the standard biotech risks: clinical setbacks, FDA scrutiny, manufacturing complexity and the need to secure sufficient funding before and after commercialization. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-recent-achievements-and-anticipated-2026-key?utm_source=openai)) Recent company updates have been constructive. In January 2026, Neurogene said multiple participants had been dosed in the Embolden registrational trial for NGN-401 and outlined 2026 milestones including additional clinical data, continued trial progress and commercial-readiness work. In March 2026, the company reported full-year 2025 financial results, and in May 2026 it reported first-quarter 2026 results. Recent SEC Form 4 filings also show ongoing insider transaction activity, which investors often monitor closely in development-stage biotech names. Overall, Neurogene remains a small-cap Nasdaq biotech story driven by a single lead program with meaningful upside if data continue to support the Rett syndrome thesis. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-recent-achievements-and-anticipated-2026-key?utm_source=openai))